Loss of TDP ‐43 Splicing Repression Occurs in Myonuclei of Inclusion Body Myositis Patients
Annals of Neurology · 2025
DOI: 10.1002/ana.27167 ↗At a glance
Journal article in Annals of Neurology, 2025. Written by Chiseko Ikenaga and 9 co-authors. Institution: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD. Major MEDLINE topics: DNA-Binding Proteins, Myositis, Inclusion Body, Muscle, Skeletal, RNA Splicing. Cited 11 times so far (Crossref); 48 references. The full text is freely available in PubMed Central. Funded by: NINDS NIH HHS, NIAMS NIH HHS, Myositis Association.
Abstract (original language)
Objective
Inclusion body myositis (IBM) is an idiopathic inflammatory myopathy with muscle pathology characterized by endomysial inflammation, rimmed vacuoles, and cytoplasmic mislocalization of transactive response DNA‐binding protein 43 (TDP‐43). We aimed to determine whether loss of TDP‐43 splicing repression led to the production of “cryptic peptides” that could be detected in muscle biopsies as a useful biomarker for IBM.
Methods
We used an antisera against a neoepitope encoded by a TDP‐43‐dependent cryptic exon within hepatoma‐derived growth factor‐like protein 2 ( HDGFL2 ) for immunohistochemical analysis on muscle biopsy samples of 122 patients with IBM, 181 disease controls, and 16 healthy controls without abnormal muscle pathology. In situ hybridization was also utilized to detect the localization of cryptic HDGFL2 transcripts.
Results
We found cryptic HDGFL2 peptides localized within myonuclei from muscle biopsies in 79 of 122 patients with IBM (65%), and this staining correlated with TDP‐43 depletion. In contrast, cryptic HDGFL2 immunoreactivity was absent in 197 muscle biopsies from a variety of disease controls, except for 2 patients with vacuolar myopathies. Notably, we show that cryptic HDGFL2 transcripts are accompanied by the detection of cryptic HDGFL2 in muscle fibers of IBM without rimmed vacuoles and TDP‐43 aggregates.
Interpretation
Together, our findings establish that loss of TDP‐43 splicing repression occurs in myonuclei of IBM skeletal muscle and suggest that detection of cryptic peptides in muscle biopsies may be a useful biomarker. We suggest that a therapeutic strategy designed to restore TDP‐43 function should be considered to attenuate the degeneration of skeletal muscle in this devastating disease. ANN NEUROL 2025;97:629–641
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
- Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD.
- Department of Neurology, Baylor College of Medicine, Houston, TX.
ORCID profiles: Chiseko Ikenaga, Thomas E Lloyd
Funding
- NINDS NIH HHS
- NIAMS NIH HHS
- Myositis Association
- Muscular Dystrophy Association
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Neurological Disorders and Stroke
Cite
APA
Ikenaga, C., Wilson, A. B., Irwin, K. E., Peethambaran Mallika, A., Kilgore, C., Sinha, I. R., Michelle, E. H., Ling, J. P., Wong, P. C., & Lloyd, T. E. (2025). Loss of TDP ‐43 Splicing Repression Occurs in Myonuclei of Inclusion Body Myositis Patients. Annals of Neurology. https://doi.org/10.1002/ana.27167
Vancouver
Ikenaga C, Wilson AB, Irwin KE, Peethambaran Mallika A, Kilgore C, Sinha IR, et al. Loss of TDP ‐43 Splicing Repression Occurs in Myonuclei of Inclusion Body Myositis Patients. Annals of Neurology. 2025. doi:10.1002/ana.27167
BibTeX
@article{Ikenaga2025,
author = {Ikenaga, Chiseko and Wilson, Andrew B and Irwin, Katherine E and Peethambaran Mallika, Aswathy and Kilgore, Collin and Sinha, Irika R and Michelle, Elizabeth H and Ling, Jonathan P and Wong, Philip C and Lloyd, Thomas E},
title = {Loss of TDP ‐43 Splicing Repression Occurs in Myonuclei of Inclusion Body Myositis Patients},
journal = {Annals of Neurology},
year = {2025},
doi = {10.1002/ana.27167}
}
EUVIMED